FDA Advisors Endorse Rexulti for Agitation in Alzheimer’s Dementia
FDA advisors voted in favor of brexpiprazole (Rexulti) for treating agitation associated with Alzheimer’s dementia (AAD), despite increased mortality risk. By a vote of 9-1 on Friday, members of the agency’s Psychopharmacologic Drugs Advisory Committee (PDAC) and the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) said the data presented by the drug’s sponsors, […]
Managing Agitation in Schizophrenia and Bipolar Disorder
For patients with schizophrenia and bipolar disorder who exhibit agitation, suboptimal treatments have been overused while better-tolerated and possibly more-effective interventions have been underused, according to findings reported at Psych Congress, held virtually and in San Antonio. In this first of four exclusive episodes, MedPage Today brought together three expert leaders in the field — […]